

Table 1	
Variable	Value
Age	25.0
Sex	Male
Height	1.75
Weight	70.0
Heart rate	75.0
Stroke volume	100.0
Cardiac output	7.5
Systemic pressure	120/80
Pulmonary pressure	25/15
Pulmonary flow	5.0
Arterial oxygen saturation	98%
Mixed venous oxygen saturation	75%
Arterial oxygen tension	100 mmHg
Mixed venous oxygen tension	40 mmHg
Arterial carbon dioxide tension	40 mmHg
Mixed venous carbon dioxide tension	45 mmHg
Arterial pH	7.4
Mixed venous pH	7.35
Arterial bicarbonate	24 mmol/L
Mixed venous bicarbonate	26 mmol/L
Arterial lactate	1.0 mmol/L
Mixed venous lactate	2.0 mmol/L
Arterial glucose	100 mg/dL
Mixed venous glucose	80 mg/dL
Arterial insulin	10 uU/mL
Mixed venous insulin	15 uU/mL
Arterial epinephrine	0.1 ng/mL
Mixed venous epinephrine	0.2 ng/mL
Arterial norepinephrine	0.1 ng/mL
Mixed venous norepinephrine	0.2 ng/mL
Arterial renin	1.0 ng/mL
Mixed venous renin	1.5 ng/mL
Arterial aldosterone	10 ng/mL
Mixed venous aldosterone	15 ng/mL
Arterial ANP	100 pg/mL
Mixed venous ANP	150 pg/mL
Arterial BNP	100 pg/mL
Mixed venous BNP	150 pg/mL
Arterial C-peptide	1.0 ng/mL
Mixed venous C-peptide	1.5 ng/mL
Arterial insulin-like growth factor	1.0 ng/mL
Mixed venous insulin-like growth factor	1.5 ng/mL
Arterial growth hormone	1.0 ng/mL
Mixed venous growth hormone	1.5 ng/mL
Arterial prolactin	1.0 ng/mL
Mixed venous prolactin	1.5 ng/mL
Arterial cortisol	1.0 ng/mL
Mixed venous cortisol	1.5 ng/mL
Arterial testosterone	1.0 ng/mL
Mixed venous testosterone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng/mL
Mixed venous estrone	1.5 ng/mL
Arterial estradiol	1.0 ng/mL
Mixed venous estradiol	1.5 ng/mL
Arterial progesterone	1.0 ng/mL
Mixed venous progesterone	1.5 ng/mL
Arterial estrone	1.0 ng

My residence, post office address and citizenship are as stated below, next to my name.

ELECTRONIC GATHERING OF PRODUCT INFORMATION AND PURCHASING OF PRODUCTS

X is attached hereto.
_____ was filed on _____ as

United States Application Number _____
or PCT International Application Number _____
and was amended on _____.

(if applicable)

I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

<u>Prior Foreign Application(s)</u>			<u>Priority Claimed</u>	
<u>(Number)</u>	<u>(Country)</u>	<u>(Foreign Filing Date)</u>	<u>Yes</u>	<u>No</u>
<u>(Number)</u>	<u>(Country)</u>	<u>(Foreign Filing Date)</u>	<u>Yes</u>	<u>No</u>
<u>(Number)</u>	<u>(Country)</u>	<u>(Foreign Filing Date)</u>	<u>Yes</u>	<u>No</u>

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

Application Number

(Filing Date)

Application Number

(Filing Date)

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Number

Filing Date

Status -- patented,
pending, abandoned

Application Number


Filing Date

Status -- patented,
pending, abandoned

I hereby appoint the persons listed on Appendix A hereto (which is incorporated by reference and a part of this document) as my respective patent attorneys and patent agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

Send correspondence to Customer No. 008791, (BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP, 12400 Wilshire Boulevard 7th Floor, Los Angeles, California 90025) and direct telephone calls to Gregg A. Peacock, Reg. No. 45,001, (512) 330-0844.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First/Sole Inventor Hiroshi Ogino
Inventor's Signature  Date 9/21/2001
Residence Palo Alto, California Citizenship Japan
(City, State) (Country)
Post Office Address 501 Forest Avenue, #1004
Palo Alto, California 94301

080398.P460

APPENDIX A

William E. Alford, Reg. No. 37,764; Farzad E. Amini, Reg. No. 42,261; William Thomas Babbitt, Reg. No. 39,591; Carol F. Barry, Reg. No. 41,600; Jordan Michael Becker, Reg. No. 39,602; Lisa N. Benado, Reg. No. 39,995; Bradley J. Berezna, Reg. No. 33,474; Michael A. Bernadicou, Reg. No. 35,934; Roger W. Blakely, Jr., Reg. No. 25,831; R. Alan Burnett, Reg. No. 46,149; Gregory D. Caldwell, Reg. No. 39,926; Thomas M. Coester, Reg. No. 39,637; Donna Jo Coningsby, Reg. No. 41,684; Florin Corie, Reg. No. 46,244; Dennis M. deGuzman, Reg. No. 41,702; Stephen M. De Klerk, Reg. No. 46,503; Michael Anthony DeSanctis, Reg. No. 39,957; Daniel M. De Vos, Reg. No. 37,813; Justin M. Dillon, Reg. No. 42,486; Sanjeet Dutta, Reg. No. 46,145; Matthew C. Fagan, Reg. No. 37,542; Tarek N. Fahmi, Reg. No. 41,402; George Fountain, Reg. No. 37,374; James Y. Go, Reg. No. 40,621; James A. Henry, Reg. No. 41,064; Libby N. Hope, Reg. No. 46,774; Willmore F. Holbrow III, Reg. No. 41,845; Sheryl Sue Holloway, Reg. No. 37,850; George W. Hoover II, Reg. No. 32,992; Eric S. Hyman, Reg. No. 30,139; William W. Kidd, Reg. No. 31,772; Sang Hui Kim, Reg. No. 40,450; Walter T. Kim, Reg. No. 42,731; Eric T. King, Reg. No. 44,188; George Brian Leavell, Reg. No. 45,436; Kurt P. Leyendecker, Reg. No. 42,799; Gordon R. Lindeen III, Reg. No. 33,192; Jan Carol Little, Reg. No. 41,181; Robert G. Litts, Reg. No. 46,876; Joseph Lutz, Reg. No. 43,765; Michael J. Mallie, Reg. No. 36,591; Andre L. Marais, under 37 C.F.R. § 10.9(b); Paul A. Mendonsa, Reg. No. 42,879; Clive D. Menezes, Reg. No. 45,493; Richard A. Nakashima, Reg. No. 42,023; Chun M. Ng, Reg. No. 36,878; Thien T. Nguyen, Reg. No. 43,835; Thinh V. Nguyen, Reg. No. 42,034; Dennis A. Nicholls, Reg. No. 42,036; Robert B. O'Rourke, Reg. No. 46,972; Daniel E. Ovanezian, Reg. No. 41,236; Kenneth B. Paley, Reg. No. 38,989; Gregg A. Peacock, Reg. No. 45,001; Marina Portnova, Reg. No. 45,750; Randol W. Read, Reg. No. 43,876; William F. Ryann, Reg. No. 44,313; James H. Salter, Reg. No. 35,668; William W. Schaal, Reg. No. 39,018; James C. Scheller, Reg. No. 31,195; Jeffrey S. Schubert, Reg. No. 43,098; George P. Simion, Reg. No. 47,089; Jeffrey Sam Smith, Reg. No. 39,377; Maria McCormack Sobrino, Reg. No. 31,639; Stanley W. Sokoloff, Reg. No. 25,128; Judith A. Szepesi, Reg. No. 39,393; Ronald S. Tamura, Reg. No. 43,179; Vincent P. Tassinari, Reg. No. 42,179; Edwin H. Taylor, Reg. No. 25,129; John F. Travis, Reg. No. 43,203; Joseph A. Twarowski, Reg. No. 42,191; Tom Van Zandt, Reg. No. 43,219; Lester J. Vincent, Reg. No. 31,460; Glenn E. Von Tersch, Reg. No. 41,364; John Patrick Ward, Reg. No. 40,216; Mark L. Watson, Reg. No. 46,322; Thomas C. Webster, Reg. No. 46,154; and Norman Zafman, Reg. No. 26,250; my patent attorneys, and Firasat Ali, Reg. No. 45,715; Peggy Susan Howard Avalos, Reg. No. 42,274; Thomas S. Ferrill, Reg. No. 42,532; Charles P. Landrum, Reg. No. 46,855; and Raul Martinez, Reg. No. 46,904, my patent agents, of BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP, with offices located at 12400 Wilshire Boulevard, 7th Floor, Los Angeles, California 90025, telephone (310)207-3800; and James R. Thein, Reg. No. 31,710, my patent attorney, with offices at 2231 Crystal Drive, Suite 108, Arlington, VA 22202, telephone (703)521-6525; with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

APPENDIX B

Title 37, Code of Federal Regulations, Section 1.56 Duty to Disclose Information Material to Patentability

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

(1) Prior art cited in search reports of a foreign patent office in a counterpart application, and

(2) The closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or

(2) It refutes, or is inconsistent with, a position the applicant takes in:

(i) Opposing an argument of unpatentability relied on by the Office, or

(ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

(1) Each inventor named in the application;

(2) Each attorney or agent who prepares or prosecutes the application; and

(3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.